yesterday and set a price target of $9.00. Eric Joseph has given his Sell rating due to a combination of factors affecting Novavax’s current and future performance. One major concern is the company’s ...

TD Cowen lowered the firm’s price target on Novavax (NVAX) to $9 from $14 and keeps a Hold rating ... Q3 COVID vaccine revenues missed as expected, given delayed start as the low initial market share ...

Analysts are estimating that Novavax will report an earnings per share (EPS) of $-0.87. Anticipation surrounds Novavax's ...

Besides Sanofi deal for nuvaxovid, Novavax has few opportunities to generate additional revenue, which likely means its stock ...

Novavax (NVAX) delivered earnings and revenue surprises of 12.64% and 47.43%, respectively, for the quarter ended September 2024. Do the numbers hold clues to what lies ahead for the stock?

Novavax, Inc. (NASDAQ:NVAX – Get Free Report) has been assigned an average rating of “Hold” from the six brokerages that are presently covering the company, Marketbeat.com reports. One research ...

Novavax (NVAX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Neurogene shares tumbled 35% last night after it disclosed that a pediatric patient with Rett syndrome experienced a severe ...

NEW YORK, NY / ACCESSWIRE / November 8, 2024 / Pomerantz LLP is investigating claims on behalf of investors of Novavax, Inc. ("Novavax" or the "Company") (NASDAQ:NVAX). Such investors are advised to ...